Press Release- Financial Results for the quarter ended 30th June 2026
Press Release - Q1FY27
- Revenue 756.3 Cr +37.1% y-y; EBITDA 111.7 Cr +60.7% y-y; PAT 64.5 Cr +89.9% y-y
- Pharmaceuticals revenue up 43% y-y; EBIT up 72% y-y; non-Ibuprofen products 43% of pharma revenue
- Chemicals revenue up 29% y-y; EBIT up 193% y-y; improved efficiencies and exports
- Exports 28.5% of revenue vs 24.4% in Q1FY26; Clopidogrel API approved in China
- Focus on portfolio scaling, capacity utilization, value-added APIs, and specialty chemicals
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 IOLCP — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add IOLCP to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on IOL Chemicals and Pharmaceuticals Limited
Important.
The summary above is generated automatically from IOL Chemicals and Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.